Sign In
Buy CXW
Corrections of America Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | $0.480 |
| EPS actual | $0.480 |
| Revenue estimate | 575.846M |
| Revenue actual | 580.437M |
| Revenue Surprise | 0.797% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.430 |
| EPS actual | $0.590 |
| EPS Surprise | 37.21% |
| Revenue estimate | 520.354M |
| Revenue actual | 538.165M |
| Revenue Surprise | 3.42% |
| Release date | May 07, 2025 |
| EPS estimate | $0.350 |
| EPS actual | $0.450 |
| EPS Surprise | 28.57% |
| Revenue estimate | 478.494M |
| Revenue actual | 488.627M |
| Revenue Surprise | 2.12% |
| Release date | Feb 10, 2025 |
| EPS estimate | $0.330 |
| EPS actual | $0.390 |
| EPS Surprise | 18.18% |
| Revenue estimate | 465.166M |
| Revenue actual | 479.293M |
| Revenue Surprise | 3.04% |
Last 4 Quarters for Corrections of America
Below you can see how CXW performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 10, 2025 |
| Price on release | $18.84 |
| EPS estimate | $0.330 |
| EPS actual | $0.390 |
| EPS surprise | 18.18% |
| Date | Price |
|---|---|
| Feb 04, 2025 | $18.88 |
| Feb 05, 2025 | $19.25 |
| Feb 06, 2025 | $18.76 |
| Feb 07, 2025 | $18.43 |
| Feb 10, 2025 | $18.84 |
| Feb 11, 2025 | $18.04 |
| Feb 12, 2025 | $19.18 |
| Feb 13, 2025 | $19.06 |
| Feb 14, 2025 | $18.83 |
| 4 days before | -0.212% |
| 4 days after | -0.0531% |
| On release day | -4.25% |
| Change in period | -0.265% |
| Release date | May 07, 2025 |
| Price on release | $22.60 |
| EPS estimate | $0.350 |
| EPS actual | $0.450 |
| EPS surprise | 28.57% |
| Date | Price |
|---|---|
| May 01, 2025 | $22.79 |
| May 02, 2025 | $22.89 |
| May 05, 2025 | $22.96 |
| May 06, 2025 | $23.06 |
| May 07, 2025 | $22.60 |
| May 08, 2025 | $22.02 |
| May 09, 2025 | $21.88 |
| May 12, 2025 | $21.64 |
| May 13, 2025 | $21.72 |
| 4 days before | -0.83% |
| 4 days after | -3.89% |
| On release day | -2.57% |
| Change in period | -4.70% |
| Release date | Aug 06, 2025 |
| Price on release | $19.60 |
| EPS estimate | $0.430 |
| EPS actual | $0.590 |
| EPS surprise | 37.21% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $20.04 |
| Aug 01, 2025 | $19.61 |
| Aug 04, 2025 | $19.66 |
| Aug 05, 2025 | $20.11 |
| Aug 06, 2025 | $19.60 |
| Aug 07, 2025 | $20.00 |
| Aug 08, 2025 | $20.50 |
| Aug 11, 2025 | $20.19 |
| Aug 12, 2025 | $20.70 |
| 4 days before | -2.20% |
| 4 days after | 5.61% |
| On release day | 2.04% |
| Change in period | 3.29% |
| Release date | Nov 05, 2025 |
| Price on release | $18.64 |
| EPS estimate | $0.480 |
| EPS actual | $0.480 |
| Date | Price |
|---|---|
| Oct 30, 2025 | $18.32 |
| Oct 31, 2025 | $18.53 |
| Nov 03, 2025 | $18.85 |
| Nov 04, 2025 | $18.43 |
| Nov 05, 2025 | $18.64 |
| Nov 06, 2025 | $16.79 |
| Nov 07, 2025 | $16.95 |
| Nov 10, 2025 | $17.44 |
| Nov 11, 2025 | $17.23 |
| 4 days before | 1.75% |
| 4 days after | -7.56% |
| On release day | -9.92% |
| Change in period | -5.95% |
Corrections of America Earnings Call Transcript Summary of Q3 2025
CoreCivic reported a busy Q3 2025 driven by reactivations and new contracts. Management announced four contract awards (West Tennessee 600 beds; California City 2,560 beds; Midwest Regional Reception Center 1,033 beds; Diamondback 2,160 beds) that together are expected to generate approximately $320 million of annual revenue at stabilized occupancy. The company expects to reach ~ $2.5 billion annual run-rate revenue and to increase annual run-rate adjusted EBITDA by about $100 million to over $450 million once these activations stabilize (expected in H1–Q2 2026). Q3 results: GAAP EPS $0.24, adjusted EBITDA $88.8M (up 6.6% YoY), adjusted EPS and normalized FFO per share modestly beat internal forecasts. Management lowered full-year 2025 guidance modestly (adjusted EPS, normalized FFO and adjusted EBITDA ranges) because of start-up losses and higher CapEx tied to the new activations; they estimate the EBITDA reduction from the four activations to be about $10–11M versus prior guidance. Share repurchases are a key capital allocation priority: the company has repurchased 20.4M shares since May 2022, has ~$198M remaining authorization, and plans to accelerate buybacks (Q4 cadence expected to be at least double Q3). Liquidity: $56.6M cash and ~$191M available on revolver (total liquidity ~$248M); net debt/adjusted EBITDA ~2.5x. Risks/notes for investors: intake at the Midwest facility is delayed by a lawsuit brought by the City of Leavenworth (DOJ recently entered the case); activations have start-up losses and timing can be lumpy and partly outside CoreCivic’s control (pace of ICE intake, legal outcomes). CEO Damon Hininger will step down as CEO effective January 1, 2026 (Patrick Swindle named successor).
